Bought a few of these as the news seems to be getting better and I am sure we have now seen the bottom

ains




Maelor Approved to Hold CE Marks


Maelor plc, the AIM quoted specialist healthcare products company, is pleased to
announce that its wholly-owned subsidiary, Maelor Pharmaceuticals Limited, has
been certified to hold its own CE Marks for medical devices associated with
sterile catheter irrigation solutions.


Maelor CEO Stephen Appelbee said:


'This approval is important because it will enable us to develop and launch our
own product brands using a Maelor CE Mark. This now allows us to accelerate the
launch programme of our range of sterile catheter irrigation solutions into
several worldwide markets under our own brand. Now that we have established our
certified status it will be a straightforward process to extend this to other
devices being developed from our pipeline.


It is also formal recognition that Maelor maintains the highest quality
standards in the development and manufacture of its products

you could well be right, I am expecting a slight fall back, but todate the SP has held up quite well in the face of heavy daily late selling.

However I have set aside some funds for any sign of weakness, so I cant really lose either way.

We should get news next month or early Sept, and which by all accounts should be quite good and very encouraging for any future potential investors to consider,.

This still remains a very mis-undertood and grossly undervalued company in my opinion of course, as I would not wish to be seem ramping.

As said previously, in that case please "dont buy it" as the MLR SP will talk for itself.

Thank you for the opportunity to answer you and please enjoy your weekend.

It's going to be more than a slight fall back....

Whatever you say Sir, as you obviously know best.

Please tell me is this comment on MLR coming from your same source that said both BKE and COH would be going up?

I just like to get my sources and facts as right as possible.

You are correct, I do know best and COH will be 50p very soon and BKE will be 1p in the very near future...

I am so pleased your confidence is showing through, even though its somewhat misguided and rather unsustainable.

Frankly I like fairytales too, but there is little place for them on the LSE/

OK...ORIGINAL MR COOL.


LOLOLOLOLOL

you called it daddy O

Anyway lets get back to basics...MLR will begin to fall again next without news.

iF YOU SAY SO THEN IT MUST BE SO. PERSONALLY I WOULD BE RATHER MORE PRUDENT AND WAIT FOR THE SP TO TALK TO ME.

No news...no profit...no rise.

that normally applies I would agree.

I "sgree"...

Could you be slightly inebriated old boy?

Or just peeeeeeeeeeeed off at being discovered ramping?

Down as I predicted and more to come...no news no rise only way is down.

...and down it goes again.

of course you realise that there us a huge overhang from the placing at 10p, this in effect could see the SP fall at lot further.

I am rather surprised its holding up so well at these levels but its a good sign of a quality company

nice recovery towards the end of the day--very encourgaing indeed.

Still need to be careful though plenty of sellers about, why I will never work out.

Trigger you have some work do do now please, ie keep the thread clean. I have been asked to delier a light plane to Eire will be away for a while.

Have fun people. Make money and keep your chins up.

Updated TA

Very pleased with the solid set of results and it's looking good for the next 12/18months... I'm hanging in there for the 20p+ levels which I think will be achieved gradually (IMHO)(got in at 11.5p some 2yrs back).........

Maelor PLC
06 November 2007

6th November 2007


Maelor plc (the 'Company' or the 'Group') - Interim Results

Maelor transformed to deliver profits ahead of expectations

Maelor plc, the UK based specialist hospital medicines group, is pleased to
announce its interim results for the six months ended 30 September 2007.

Financial Highlights

Transformational results ahead of expectations

Turnover up 132% to 3.1 million (H1 2006: 1.3 million)
Profit before tax of 0.7 million (H1 2006: loss 0.07 million)
Sustainable gross margin improvement to 57% (H1 2006: 46%)
Interim earnings per share of 0.48p (H1 2006: loss 0.22p)
Net cash balance increased to 1.7 million (H1 2006: 1.1 million)

Operational Highlights

Transformation delivered through determined implementation of strategy

Growing portfolio through acquisition and licensing
Transforming acquisition of Acorus Therapeutics Limited - Integration
completed ahead of schedule
International distributor network established
Licensing of Aloxi(R) from Helsinn - launch scheduled for March 2008

Driving growth from launched brands
Strengthened commercial team to drive sales
Volplex(R) market share driven from 16% (H1 2006) to 26%
Cryogesic(R) sales growing and expansion plans implemented
Mysoline(R) transfer and introduction completed in all major
territories ahead of schedule

Partnering non-core portfolio
Partnership with Bard for OptiFloTM catheter maintenance solutions
extended

- Market leadership position maintained at 54% market share

Micelle nanotechnology collaboration with Plethora Solutions Limited
progressing well

Rapidly progressing pipeline
Haemopressin(R) and ISOplexTM on schedule for launch in H2 2008/09
GentisprayTM phase III programme on schedule
Mysoline(R) development programme in Essential Tremor initiated


Commenting on the results Tim Wright, CEO, said:

'I am very pleased to be able to report such positive results, which are ahead
of expectations and reinforce the robustness of our strategy.

'In addition to our strong portfolio of marketed brands in the UK and
internationally we have built an impressive pipeline of late stage products.
These assure the continued growth of the business which we will accelerate
through further acquisition and licensing.

'Trading since the period end remains strong and we look to the future with
confidence.'